✦ LIBER ✦

DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes

✍ Scribed by Mi-Kyung Kim; Yu Na Chae; Ha Dong Kim; Eun Kyoung Yang; Eun Jung Cho; Song-hyen Choi; Ye-Hwang Cheong; Hae-Sun Kim; Heung Jae Kim; Yeong Woo Jo; Moon-Ho Son; Soon-Hoe Kim; Chang Yell Shin

Book ID: 116720098
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 748 KB
Volume: 90
Category: Article
ISSN: 0024-3205
DOI: 10.1016/j.lfs.2011.10.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The DPP4 inhibitor linagliptin delays th

The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves -cell mass in non-obese diabetic mice

✍ Jelsing, J.; Vrang, N.; van Witteloostuijn, S. B.; Mark, M.; Klein, T. 📂 Article 📅 2012 🏛 Bioscientifica 🌐 English ⚖ 217 KB

Chronic administration of DSP-7238, a no

Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and β-cell damage in diabetic mice

✍ Y. Furuta; M. Horiguchi; E. Sugaru; M. Ono-Kishino; M. Otani; M. Sakai; Y. Masui 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 811 KB

ChemInform Abstract: Discovery of DA-122

ChemInform Abstract: Discovery of DA-1229 (I): A Potent, Long Acting Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes.

✍ Bong Jin Lee; et al. et al. 📂 Article 📅 2011 🏛 John Wiley and Sons ⚖ 20 KB 👁 1 views

Empagliflozin, a novel potent and select

Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus

✍ G. Luippold; T. Klein; M. Mark; R. Grempler 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 701 KB

Twelve weeks treatment with the DPP-4 in

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

✍ K. Aaboe; F. K. Knop; T. Vilsbøll; C. F. Deacon; J. J. Holst; S. Madsbad; T. Kra 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 838 KB

Chronic administration of alogliptin, a

Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice

✍ Yusuke Moritoh; Koji Takeuchi; Tomoko Asakawa; Osamu Kataoka; Hiroyuki Odaka 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 808 KB